These include IL-6 blocker stuximab, IL-6R receptor blocker tolizumab, JAK inhibitor ruxolitinib, and STAT3 inhibitors, which have been shown in preclinical experiments to significantly inhibit tumor growth, increase immune cell numbers, and improve the immunosuppressive microenvironment. Here, STAT3 is linked to neoplasm.